Table 2.
Patient characteristics.
| Patient Characteristic | IV Chemotherapy (n=69) |
IV/IP Chemotherapy (n=261) |
p value |
|---|---|---|---|
| Median Age, years (range) | 63 (40 – 83) | 59 (30 – 79) | <0.001a |
|
| |||
| Median BMI, kg/m2 (range) | 24 (16 – 43) | 24 (17 – 46) | 0.16a |
|
| |||
| Total comorbidities: median (range) | 1 (0 – 3) | 0 (0 – 3) | 0.02a |
|
| |||
| Stage: n (%) | 0.41b | ||
| IIIA | 2 (3%) | 19 (7%) | |
| IIIB | 4 (6%) | 16 (6%) | |
| IIIC | 63 (91%) | 226 (87%) | |
|
| |||
| Histology: n (%) | |||
| Serous adenocarcinoma | 65 (94%) | 242 (93%) | |
| Endometrioid adenocarcinoma | 1 (1.5%) | 1 (0.4%) | |
| Clear cell carcinoma | 3 (4%) | 6 (2%) | |
| Undifferentiated carcinoma | 0 (0%) | 4 (1.5%) | |
| Mixed carcinoma | 0 (0%) | 8 (3%) | |
|
| |||
| Residual Disease: n (%) | 0.29b | ||
| No gross residual | 31 (45%) | 136 (52%) | |
| ≤1 cm | 38 (55%) | 125 (48%) | |
|
| |||
| PDS Location: n (%) | |||
| MSKCC | 53 (77%) | 201 (77%) | |
| Outside institution | 16 (23%) | 60 (23%) | |
|
| |||
| Bowel resection at PDS: n (%) | 36 (52%) | 105 (40%) | 0.07b |
|
| |||
| Ostomy at PDS: n (%) | 9 (13%) | 3 (1%) | <0.001b |
|
| |||
| IP port placed at PDS: n (%) | 37 (54%) | 215 (82%) | <0.001b |
|
| |||
| KPS at initial chemotherapy evaluation: median (range) | 80 (50 – 100) | 90 (60 – 100) | <0.001a |
|
| |||
| Participated in a clinical trial: n (%) | 8 (12%) | 57 (22%) | 0.06b |
|
| |||
| Total adjuvant chemotherapy cycles: median (range) | 6 (2 – 8) | 6 (3 – 9) | 0.75a |
IV = intravenous, IP = intraperitoneal, BMI = body mass index (weight [kg]/height [m2]), MSKCC = Memorial Sloan Kettering Cancer Center, PDS = primary debulking surgery, KPS = Karnofsky Performance Status.
a
Two-sided t-test.
b
Chi-square.